Literature DB >> 2866840

Calcium antagonists.

C R Conti, C J Pepine, R L Feldman, J A Hill.   

Abstract

At present nitrates remain the initial treatment for relief or prevention of angina in patients with coronary artery disease. In cases where nitrates and beta blockers have been used and are ineffective for managing effort angina, calcium antagonists may be substituted or added to the beta-blocking treatment. When the predominant symptom is rest angina, and there is evidence suggesting coronary artery spasm, nitrates and a calcium antagonist can be effective therapy. In patients with heart block, bradyarrhythmias, heart failure, or hypertension nifedipine may be the drug of choice. In contrast verapamil merits choice when supraventricular tachycardia is present. Diltiazem appears intermediate between nifedipine and verapamil and may be particularly useful when hypotension or other side effects must be avoided.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2866840     DOI: 10.1159/000173886

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  4 in total

Review 1.  Calcium antagonists in cerebral/peripheral vascular disorders. Current status.

Authors:  K J Tietze; M L Schwartz; P H Vlasses
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

2.  Calcium antagonistic and antiarrhythmic actions of CPU-23, a substituted tetrahydroisoquinoline.

Authors:  H Dong; J Z Sheng; C M Lee; T M Wong
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

3.  Reduction of intimal hyperplasia and enhanced reactivity of experimental vein bypass grafts with verapamil treatment.

Authors:  M N el-Sanadiki; K S Cross; J J Murray; R W Schuman; E Mikat; R L McCann; P O Hagen
Journal:  Ann Surg       Date:  1990-07       Impact factor: 12.969

4.  Cardiovascular effects of substituted tetrahydroisoquinolines in rats.

Authors:  H Dong; C M Lee; W L Huang; S X Peng
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.